Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View LXRX analyst ratings or view top-rated stocks.

1 brokers have issued 1 year price targets for Lexicon Pharmaceuticals' shares. Their LXRX share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 244.4% from the stock's current price.
View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts.

Lexicon Pharmaceuticals' stock was trading at $1.91 at the beginning of 2023. Since then, LXRX stock has decreased by 39.2% and is now trading at $1.1614.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our LXRX earnings forecast.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.05. The biopharmaceutical company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.30 million. Lexicon Pharmaceuticals had a negative net margin of 32,038.97% and a negative trailing twelve-month return on equity of 97.63%.

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (62.01%), BVF Inc. IL (8.16%), BlackRock Inc. (3.37%), JPMorgan Chase & Co. (1.55%), Pinnacle Associates Ltd. (1.05%) and Geode Capital Management LLC (0.97%). Insiders that own company stock include International SCA Artal, James F Tessmer, Jeffrey L Wade, Lonnel Coats and Wendy Mcdermott.
View institutional ownership trends.

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LXRX stock can currently be purchased for approximately $1.16.

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $284.46 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

The company employs 135 workers across the globe.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.